Sunshine Biopharma Inc. · NASDAQ:SBFM
Sunshine Biopharma — Investor Presentation (February 2022)
15 slides from Sunshine Biopharma's investor presentation, Feb 8, 2022
Slide 1: Sunshine Biopharma Inc. (OTC Markets: SBFM)
Sunshine Biopharma Inc. (OTC Markets: SBFM)
Slide 2: Forward-Looking Statements
` To the extent that statements in this presentation are not strictly historical, including statements as to revenue projections, future estimates, plans, programs, forecasts, objectives, assumptions, expectations, marketing and sales plans, anticipated revenues, projected market size, beliefs of fu
Slide 3: What We Do
Sunshine Biopharma is focused on the research, development and commercialization of Oncology and Antiviral drugs . Additional activity of Science Based Nutritional Supplements What We Do
Slide 4: R&D Pipeline
Drug Candidate Indication Time to Phase I Market Size Adva - 27 a Pancreatic Cancer 9 - 18 Months >> $ 1 Billion SBFM - PL 4 COVID - 19 9 - 18 Months Multi Billion R&D Pipeline Drug Candidate Indication Time to Phase I Market Size Adva - 27 a Pancreatic Cancer 9 - 18 Months >> $ 1 Billion SBFM - PL
Slide 5: Oncology Drug Development
Oncology Drug Development □ In the area of Oncology, we are developing a chemotherapy small molecule called Adva - 27 a □ Adva - 27 a has the uncommon property of being effective against Multidrug Resistant cancer cells □ All Patents pertaining to Adva - 27 a are owned by the Company □ Patent covera
Slide 6: Multidrug Resistance
Multidrug Resistance □ Multidrug Resistance represents a major challenge in cancer therapy □ Cancers can be Multidrug Resistant upon diagnosis (e.g. pancreatic cancer ) or become Multidrug Resistant over time □ Multidrug Resistant cancers do not respond to chemotherapy drugs in common use □ At prese
Slide 7: Adva-27a Kills Multidrug Resistant Cancer Cells
Adva - 27a Kills Multidrug Resistant Cancer Cells Adva - 27a Kills Multidrug Resistant Breast Cancer Cells, Pancreatic Cancer Cells, Small - Cell Lung Cancer Cells, and Uterine Sarcoma Cells
Slide 8: Summary of Adva-27a Preclinical Results
Summary of Adva - 27a Preclinical Results We have recently completed and published our preclinical studies . Adva - 27 a was found to have unique pharmaceutical properties . Our results have shown that : • Adva - 27a is effective at killing different types of multidrug resistant cancers, including:
Slide 9: Antiviral Drug Development
□ In the area of Antivirals, we are focused on the development of a treatment for COVID - 19 □ We have been working on this project since April 2020 □ In the meantime, three vaccines (Pfizer’s, Moderna’s, and Johnson & Johnson’s), two antibody treatments (Regeneron’s, and Eli Lilly’s), one injectabl
Slide 10: Our SBFM-PL4 Targets a Different Part of The Virus
Adapted and modified from PNAS 103: 5717 – 5722 (2006) Our SBFM - PL4 Targets a Different Part of The Virus □ Our SBFM - PL 4 is nsp 3 protease inhibitor , currently being developed in collaboration with the University of Georgia □ nsp 3 is the protease responsible for suppression of the human immun
Slide 11: Science Based Nutritional Supplements
Science Based Nutritional Supplements □ Essential 9 TM is our first product in this space □ Essential 9 TM is a tablet that contains the 9 Amino Acids that the human body cannot make . These are called Essential Amino Acids □ Deficiency in one or more of the 9 Essential Amino Acids can lead to loss
Slide 12: Upcoming Milestones
Upcoming Milestones Adva - 27a Drug Development Program: » GMP Manufacturing (5 Kilograms) » IND - Enabling Studies » Filing of IND Application (“Fast - Track” anticipated) » Phase I Clinical Trials (Pancreatic Cancer, Jewish General Hospital ) Antiviral Program: » Efficacy Studies in Coronavirus In
Slide 13: Current Capitalization
Outstanding Shares 2 , 591 , 241 ( as adjusted for 200 to 1 reverse split) Outstanding Warrants None Outstanding Options None Outstanding Debt $ 1 , 900 , 000 ( principal amount) Current Capitalization Outstanding Shares 2 , 591 , 241 (as adjusted for 200 to 1 reverse split) Outstanding Warrants Non
Slide 14: Management
Steve N . Slilaty, Ph . D . Molecular Biologist Univ . of Arizona CEO Sunshine Biopharma is the third in a line of biotechnology companies that Dr . Slilaty founded and managed . The first, Quantum Biotechnologies Inc . later known as Qbiogene Inc . , was founded in 1991 and is now a member of a fam
Slide 15: Thank You for Your Attention!
Sunshine Biopharma Inc. (OTC Markets: SBFM) Thank You for Your Attention! www.SunshineBiopharma.com
Sunshine Biopharma — Investor Presentation (February 2022) on 6ix